Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A I Green

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Advances in Biochemical Psychopharmacology|January 1, 1973
The role of the federal government in the development of narcotic antagonistsA I Green
Hospital & Community Psychiatry|December 1, 1984
Thyroid function and affective disordersA I Green
The Harvard Mental Health Letter|October 4, 2000
What is the relationship between schizophrenia and substance abuse?A I Green
Harvard Review of Psychiatry|May 1, 1994
Psychosis, delirium, or both?M Kahn, A I Green
Hospital & Community Psychiatry|April 1, 1990
Clozapine: benefits and risksA I Green, C Salzman
The Journal of Nervous and Mental Disease|February 1, 1991
Effect of personality disorders on outcome of treatmentJ H Reich, A I Green
Harvard Review of Psychiatry|May 1, 1995
Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patientsA I Green, J J Schildkraut
Neurologic Clinics|February 1, 1988
Prolactin and neuroleptic drugsA I Green, W A Brown
Endocrinology and Metabolism Clinics of North America|March 1, 1988
Prolactin and neuroleptic drugsA I Green, W A Brown
Psychosomatics|May 1, 1993
Psychopathology of pancreatic cancer. A psychobiologic probeA I Green, C P Austin
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Advances in Biochemical Psychopharmacology|January 1, 1973
The role of the federal government in the development of narcotic antagonistsA I Green
Hospital & Community Psychiatry|December 1, 1984
Thyroid function and affective disordersA I Green
The Harvard Mental Health Letter|October 4, 2000
What is the relationship between schizophrenia and substance abuse?A I Green
Harvard Review of Psychiatry|May 1, 1994
Psychosis, delirium, or both?M Kahn, A I Green
Hospital & Community Psychiatry|April 1, 1990
Clozapine: benefits and risksA I Green, C Salzman
The Journal of Nervous and Mental Disease|February 1, 1991
Effect of personality disorders on outcome of treatmentJ H Reich, A I Green
Harvard Review of Psychiatry|May 1, 1995
Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patientsA I Green, J J Schildkraut
Neurologic Clinics|February 1, 1988
Prolactin and neuroleptic drugsA I Green, W A Brown
Endocrinology and Metabolism Clinics of North America|March 1, 1988
Prolactin and neuroleptic drugsA I Green, W A Brown
Psychosomatics|May 1, 1993
Psychopathology of pancreatic cancer. A psychobiologic probeA I Green, C P Austin
Pageof 5